Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Carcinoma, Small Cell 1Carcinoma in Situ 1Breast Neoplasms 1

Interventions

Topotecan 4Cisplatin 4Etoposide 3belinostat 2Pemetrexed 2Paclitaxel 2Carboplatin 2vosaroxin 1vinflunine 1veliparib 1taxane 1sagopilone 1pembrolizumab 1lurtotecan 1liposomal doxorubicin 1belotecan 1Vinorelbine 1Tomography, X-Ray Computed 1Temozolomide 1Taxes 1Sorafenib 1RRx-001 1Quality of Life 1Positron-Emission Tomography 1Podophyllotoxin 1Platinum 1Patient Reported Outcome Measures 1PT-100 dipeptide 1Nortriptyline 1Molecular Diagnostic Techniques 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma, Small Cell × Histamine Antagonists × Clear all
NCT03554473 2025-05-09

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
37 enrolled 19 charts
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡